NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-10-26 23:15இன்று 29 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Sumitomo Chemical Q2FY27 Investor Presentation: PAT Down 11% YoY to Rs 157 Cr, Revenue Down 2%
Sumitomo Chemical India released its Q2 & H1 FY27 investor presentation, reporting a 2% YoY dip in Q2FY27 revenue to Rs 907 crore and an 11% decline in PAT to Rs 157 crore. Performance was impacted by high-cost inventory absorption and weak seasonal demand due to a delayed monsoon and a 13% rainfall deficit. Domestic revenue grew 2% YoY to Rs 774 crore, but exports dropped 23% YoY to Rs 127 crore. For H1FY27, revenue stood at Rs 1,971 crore with EBITDA down 4% to Rs 419 crore, supported by an exceptional insurance claim of Rs 26.9 crore received in Q1.
உச்சம் நம்பிக்கை
என்ன மாறியதுSumitomo Chemical released its detailed quarterly presentation outlining H1FY27 and Q2FY27 operational performance and product launches.
ஏன் இது முக்கியம்Demonstrates margin compression caused by high-cost inventory carryover and export weakness, while providing visibility on domestic demand resilience and new product rollouts.
📅 குறுகிய காலம்Margin pressure in Q2 reflects inventory-cost lag that normalized by quarter-end, but weak H2 seasonality and reservoir deficit remain near-term headwinds.
📈 நீண்ட காலம்Access to parent Sumitomo Chemical Japan's R&D, product launches like Topgrain, and ongoing capex execution support medium-term specialty chemical growth.
⚠ அபாய எச்சரிக்கைகள்
Lower reservoir levels and extended El Nino impact posing acreage constraints in H2
Export demand volatility (down 23% in Q2)
High-cost inventory absorption risk
👀 கவனிக்க வேண்டியவை
Track volume recovery in H2FY27 following reservoir level monitoring and potential acreage constraints, as well as the commercialization progress of capex projects.
Sumitomo Chemical Q2 FY27 Standalone PAT Declines 12.3% YoY to ₹156.04 Cr; Revenue at ₹890.91 Cr
Sumitomo Chemical India reported a 2.6% YoY drop in standalone revenue from operations to ₹890.91 Cr (₹8,909.08 Mn) for Q2 FY27 compared to ₹914.44 Cr (₹9,144.44 Mn) in Q2 FY26. Standalone profit after tax dropped 12.3% YoY to ₹156.04 Cr (₹1,560.42 Mn) from ₹177.90 Cr (₹1,778.97 Mn), with diluted EPS slipping to ₹3.13 from ₹3.56. For H1 FY27, net profit stood at ₹372.57 Cr, up 4.2% YoY supported by an exceptional gain of ₹26.90 Cr recorded in Q1.
உச்சம் நம்பிக்கை
என்ன மாறியதுReported Q2 FY27 results indicating contraction in both top-line (-2.6% YoY) and bottom-line (-12.3% YoY).
ஏன் இது முக்கியம்Reflects continuing pressure in agrochemical demand and insect infestation levels, squeezing operating leverage and margins relative to previous quarters.
Revenue from operations (Q2): ₹8,909.08 MnNet Profit (Q2): ₹1,560.42 MnEPS (Q2): ₹3.13H1 Net Profit: ₹3,725.71 Mn
📅 குறுகிய காலம்Earnings decline is likely to exert short-term pressure on the stock, given the 12.3% YoY dip in quarterly net profit and ongoing weakness in key agrochem markets.
📈 நீண்ட காலம்Structural advantages remain backed by parent Sumitomo Chemical Japan and a net-debt-free balance sheet, though sustained growth relies on new product scale-up and export normalization.
⚠ அபாய எச்சரிக்கைகள்
Continued demand softness in domestic or export agrochemical markets
Pressure on operating margins due to fixed-cost under-absorption
👀 கவனிக்க வேண்டியவை
Monitor volume growth trends in the domestic agrochemical business and the pace of export recovery in upcoming quarters, alongside the commercialization timeline of the five new products under the ₹120 Cr capex.
₹1.30 Dividend and MD Transition Approved; 31% Institutional Dissent on Advisory Fees
Sumitomo Chemical India shareholders approved all 10 resolutions at the AGM held on July 27, 2026, including a dividend of ₹1.30 per share. A major leadership transition was ratified, with Dr. Suresh Ramachandran promoted to Managing Director effective September 1, 2026, succeeding Mr. Chetan Shah. Notably, Resolution 8 regarding advisory fees for the outgoing MD faced 31.04% dissent from institutional investors, though it passed. Material related party transactions with the Japanese parent for FY27 were also cleared.
உச்சம் நம்பிக்கை
என்ன மாறியதுFormal approval of the FY26 dividend and the transition of the Managing Director role from Mr. Chetan Shah to Dr. Suresh Ramachandran.
ஏன் இது முக்கியம்Ensures leadership continuity and maintains the strategic and operational link with the Japanese parent company through approved related party transactions for proprietary products.
Dividend per share: ₹1.30Institutional Dissent (Res 8): 31.04%MD Promotion Date: 1st செப்டம்பர் 2026Total Shareholders: 112,060Dividend vs TTM EPS: ~11.9%
📅 குறுகிய காலம்Neutral; the dividend payout and management transition were expected and are likely already priced in by the market.
📈 நீண்ட காலம்The new MD's ability to leverage the parent company's R&D and execute the specialty molecule expansion will be critical for sustaining the 19-20% growth target.
⚠ அபாய எச்சரிக்கைகள்
Significant institutional dissent on advisory fees for the outgoing MD
High dependence on parent company for proprietary product pipeline
👀 கவனிக்க வேண்டியவை
Monitor the leadership transition on September 1, 2026, and track the execution of the SCI 2.0 initiative, specifically the ₹120 Cr capex aimed at adding ₹200-250 Cr in annual revenue.
Sumitomo Chemical Q1 FY27: PAT up 20% to ₹215 Cr; Major Board Reconstitution Announced
Sumitomo Chemical India (SCIL) reported a resilient Q1 FY27 with revenue growing 1% YoY to ₹1,063 crore, despite a 40% rainfall deficit impacting domestic demand. PAT rose 20% to ₹215 crore, significantly aided by a ₹26.9 crore exceptional insurance claim and a 26% surge in export revenue. EBITDA margins expanded by 120 bps to 21.9% due to disciplined pricing and a favorable product mix. The company also announced a major leadership transition effective September 1, 2026, including the appointment of a new Managing Director.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has successfully offset domestic monsoon-related weakness through export growth and margin expansion, while formalizing a major management succession plan.
ஏன் இது முக்கியம்The results demonstrate strong operating leverage and the benefit of parent Sumitomo Chemical's global supply chain. The leadership transition provides clarity on long-term governance.
📅 குறுகிய காலம்The stock may see positive sentiment due to margin resilience and the one-time insurance gain, though domestic volume growth remains a monitorable due to early-season monsoon delays.
📈 நீண்ட காலம்The 'SCI 2.0' strategy focusing on specialty molecules and the integration with the Japanese parent's R&D pipeline supports a structural growth story in the agrochemical space.
⚠ அபாய எச்சரிக்கைகள்
High channel inventory in the domestic market
Dependency on monsoon distribution for kharif and rabi seasons
Management transition execution risk
👀 கவனிக்க வேண்டியவை
Watch for the recovery in domestic volumes in Q2 as monsoon progress improved in July, and monitor the execution of the leadership transition in September. The launch of new products Topgrain and Helibax in Q2 FY27 will be key for growth momentum.
₹1.30 Dividend Approved; Dr. Suresh Ramachandran to take over as MD from Sept 2026
Sumitomo Chemical India Limited (SCIL) concluded its 26th AGM on July 27, 2026, approving a dividend of ₹1.30 per equity share for FY26. A major leadership transition was finalized, with Dr. Suresh Ramachandran promoted to Managing Director effective September 1, 2026, succeeding Mr. Chetan Shah, who will transition to a Non-Executive Director role. Shareholders also approved material related party transactions with the Japanese parent company for FY27, ensuring continued access to proprietary chemistry and products.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized its leadership succession plan and confirmed the dividend payout for the previous financial year.
ஏன் இது முக்கியம்Leadership continuity is vital for SCIL as it leverages its Japanese parent's R&D to launch high-margin specialty products; the MD transition marks a new phase in the company's growth strategy.
Dividend per share: ₹1.30Estimated Dividend Payout: ₹64.88 கோடிDividend vs TTM PAT: ~11.9%MD Transition Date: 1st செப்டம்பர் 2026AGM Attendance: 65 members
📅 குறுகிய காலம்The stock is likely to remain stable as the dividend and management changes were largely expected and follow standard corporate governance procedures.
📈 நீண்ட காலம்The transition to Dr. Ramachandran's leadership will be key to achieving the targeted 19-20% growth rate and successfully integrating the ₹120 Cr capex for new products.
⚠ அபாய எச்சரிக்கைகள்
Related-party transactions with parent company
Execution risk during leadership transition
👀 கவனிக்க வேண்டியவை
Investors should monitor the leadership transition in September 2026 and track the execution of the 'SCI 2.0' initiative under the new Managing Director.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Sumitomo Chemical Q1 Net Profit Rises 20% to ₹216.5 Cr; Revenue Flat at ₹1,054 Cr
Sumitomo Chemical India reported a 20.4% YoY increase in standalone net profit to ₹216.53 Cr for the quarter ended June 30, 2026, despite revenue remaining nearly stagnant at ₹1,054.08 Cr. The bottom line was supported by an exceptional gain of ₹26.90 Cr from an insurance claim related to a 2022-23 fire incident. Operating efficiency improved as total expenses declined slightly by 1% YoY to ₹836.77 Cr. The company's performance remains highly seasonal, with this quarter contributing approximately 32.6% of the previous year's total revenue.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported its Q1 FY27 results, showing a significant recovery in profitability and margin expansion despite a flat top-line, aided by a one-time insurance settlement.
ஏன் இது முக்கியம்The results demonstrate strong cost management and the ability to maintain profitability in a challenging agrochemical environment. The settlement of the Bhavnagar fire insurance claim removes a long-standing financial uncertainty.
Standalone Revenue (Q1): ₹1,054.08 கோடிStandalone Net Profit (Q1): ₹216.53 கோடிExceptional Insurance Gain: ₹26.90 கோடிQ1 வருவாய் vs TTM வருவாய்: 32.6%EPS (Q1): ₹4.34
📅 குறுகிய காலம்The stock may see positive sentiment due to the 20% profit growth and margin improvement, although the flat revenue growth reflects ongoing industry-wide volume/pricing pressures.
📈 நீண்ட காலம்Long-term growth is tied to the parent company's (SCCL Japan) technology transfers and the successful ramp-up of specialty high-margin molecules which are less sensitive to generic pricing cycles.
High dependency on monsoon and climatic conditions
Loss-making subsidiaries (Barrix Agro Sciences)
👀 கவனிக்க வேண்டியவை
Monitor the execution of the 'SCI 2.0' initiative and the revenue contribution from the 5 new products launched via the ₹120 Cr capex. Investors should also track the Delhi High Court's final decision on Glyphosate restrictions, as it remains a key product for the company.
Sumitomo Chemical India Proposes ₹1,623.5 Cr Related Party Transactions and New MD Appointment
Sumitomo Chemical India has issued a notice for its 26th AGM on July 27, 2026, featuring several key resolutions. Most significant is the proposal for material related party transactions (RPT) with its Japanese parent company totaling ₹1,623.5 cr for FY27, representing approximately 50% of its TTM revenue. The board also seeks to promote Dr. Suresh Ramachandran to Managing Director effective September 1, 2026. Additionally, shareholders will vote on a ₹3 cr advisory fee cap for Non-Executive Director Mr. Chetan Shah and a dividend declaration for FY26.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company is formalizing its leadership transition with a new Managing Director and setting the financial limits for its critical supply-chain relationship with its Japanese parent for the upcoming fiscal year.
ஏன் இது முக்கியம்The high volume of related party transactions (50% of revenue) underscores the company's reliance on its parent for proprietary products and raw materials, which is central to its 'SCI 2.0' growth strategy.
Proposed RPT with Parent (FY27): ₹1,623.5 கோடிRPT vs TTM Revenue: ~50.3%Advisory Fee Cap (Chetan Shah): ₹3 கோடிAGM Date: ஜூலை 27, 2026Cost Auditor Remuneration: ₹5.5 லட்சம்
📅 குறுகிய காலம்The announcement is procedural and likely to have a neutral impact on the stock price in the coming weeks as it aligns with standard annual corporate governance cycles.
📈 நீண்ட காலம்The promotion of Dr. Ramachandran to MD ensures leadership continuity as the company executes its ₹120 cr capex plan and targets 19-20% growth through specialty molecules.
⚠ அபாய எச்சரிக்கைகள்
High related-party transaction concentration (50% of revenue)
Significant advisory fees for a non-executive director exceeding 50% of total non-executive remuneration
👀 கவனிக்க வேண்டியவை
Investors should monitor the AGM voting results on July 27, 2026, specifically regarding the high-value related party transactions and the remuneration structure for non-executive directors.
Sumitomo Chemical to Approve Rs 1,623.5 Cr Related Party Transactions and New MD at July 27 AGM
Sumitomo Chemical India has scheduled its 26th AGM for July 27, 2026, to vote on several key resolutions including a massive Related Party Transaction (RPT) mandate. The company is seeking approval for transactions with its Japanese parent totaling Rs 1,623.5 Cr for FY 2026-27, which represents approximately 50.3% of its TTM revenue. Leadership changes are also on the agenda, with the proposed promotion of Dr. Suresh Ramachandran to Managing Director and the appointment of Mr. Chetan Shah as a Non-Executive Director with an advisory fee cap of Rs 3 Cr. These moves formalize the company's deep operational integration with its parent and its long-term leadership structure.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company is initiating a leadership transition with a new Managing Director and setting formal financial limits for its extensive supply chain and service dependencies on its Japanese parent company.
ஏன் இது முக்கியம்The RPT volume (50% of revenue) highlights the company's core strategy of leveraging its parent's proprietary chemistry; leadership continuity is vital for the 'SCI 2.0' initiative and the planned Rs 120 Cr capex execution.
RPT with Parent (FY27): Rs 1,623.5 கோடிRPT vs TTM Revenue: 50.3%Advisory Fee Cap (Mr. Chetan Shah): Rs 3 கோடிAGM Date: ஜூலை 27, 2026Cost Auditor Fee: Rs 5.5 Lakhs
📅 குறுகிய காலம்The announcement is procedural and unlikely to trigger immediate price volatility; focus will remain on the dividend declaration and the upcoming AGM commentary.
📈 நீண்ட காலம்The leadership transition and sustained RPT framework suggest a stable, long-term reliance on the Japanese parent's technology and product pipeline, which is central to the company's high-margin specialty focus.
⚠ அபாய எச்சரிக்கைகள்
High concentration of Related Party Transactions (50% of revenue)
Potential minority shareholder scrutiny over Rs 3 Cr advisory fees for a Non-Executive Director
👀 கவனிக்க வேண்டியவை
Investors should monitor the AGM voting results, specifically the approval of the large RPT limits and the remuneration structure for the Non-Executive Director, to ensure alignment with minority shareholder interests.
Sumitomo Chemical India Sets July 17 as Record Date for ₹1.30 Dividend
Sumitomo Chemical India Limited has fixed July 17, 2026, as the record date to determine shareholder eligibility for a dividend of ₹1.30 per equity share for the financial year 2025-26. This announcement follows the board's decision to reward shareholders for the fiscal year's performance. Investors must hold the company's shares in their demat accounts by the record date to qualify for the payout. The notification was issued in compliance with SEBI Listing Obligations and Disclosure Requirements.
முக்கிய அம்சங்கள்
Record date for dividend eligibility is fixed for July 17, 2026.Dividend amount declared is ₹1.30 per equity share for FY 2025-26.The announcement is made pursuant to Regulation 42 of SEBI (LODR) Regulations, 2015.The dividend payout targets shareholders of record for the 2025-26 financial year.
👀 கவனிக்க வேண்டியவை
Investors seeking the dividend should ensure they own the stock before the ex-dividend date (typically one trading day before the record date). Existing shareholders should maintain their holdings through the record date to receive the ₹1.30 per share payout.
Sumitomo Chemical India FY26 PAT Rises 7% to ‡543 Cr with Record 20.7% EBITDA Margin
Sumitomo Chemical India reported its highest-ever annual profitability in FY26, with PAT growing 7% to ‡543 crores despite a challenging agrochemical environment. The company achieved record EBITDA margins of 20.7% and Gross Profit margins of 42%, driven by a shift toward branded formulations which now comprise 81% of domestic sales. Management announced a significant leadership transition effective September 2026, with Dr. Suresh Ramachandran elevated to Managing Director. While FY26 revenue grew a modest 3%, the company maintained pricing integrity and saw strong growth in the herbicide segment.
முக்கிய அம்சங்கள்
Achieved record EBITDA margin of 20.7% and Net Profit margin of 16.8% for FY26.PAT grew 7% YoY to ‡543 crores, with PBT before exceptional items rising over 9%.Herbicides segment registered 19% full-year growth, including a massive 87% jump in Q4.Branded formulation share in domestic sales improved to 81% from 79% in the previous year.Announced leadership transition: Dr. Suresh Ramachandran to succeed Chetan Shah as MD on September 1, 2026.
👀 கவனிக்க வேண்டியவை
Investors should view the record margins as a sign of strong pricing power and operational efficiency, though the 'below normal' monsoon forecast for FY27 warrants caution regarding near-term volume growth. The planned management transition appears well-structured, suggesting continuity in the company's specialty-focused strategy.
Sumitomo Chemical India FY26 PAT Up 7% to ₹543 Cr; Announces Leadership Transition
Sumitomo Chemical India (SCIL) reported a resilient performance for FY26 despite industry headwinds, with revenue growing 3% to ₹3,238 crore. The company achieved its highest-ever profitability, with PAT rising 7% to ₹543 crore and net profit margins expanding to 16.8%. A significant management transition was announced, with Dr. Suresh Ramachandran set to take over as Managing Director in September 2026. The company maintains a very strong liquidity position with cash and liquid investments totaling approximately ₹2,113 crore.
முக்கிய அம்சங்கள்
FY26 Revenue grew 3% YoY to ₹3,238 crore, while Q4FY26 revenue remained stable at ₹684 crore.Annual PAT increased 7% to ₹543 crore, despite a one-time exceptional charge of ₹16.1 crore related to new Labour Codes.EBITDA margins improved to 20.7% for FY26, driven by a favorable product mix and disciplined pricing actions.The Herbicides segment showed exceptional momentum, growing 87% YoY in Q4 and 19% for the full year.Strong balance sheet maintained with cash, cash equivalents, and liquid investments of ~₹2,113 crore as of March 2026.
👀 கவனிக்க வேண்டியவை
Investors should take confidence in the company's ability to expand margins and maintain high cash levels during a challenging year for the agrochemical sector. Monitor the leadership transition in September 2026 to ensure strategic continuity.
Sumitomo Chemical India FY26 Net Profit Rises 8% to ₹5,431 Million; Dividend of ₹1.3 Declared
Sumitomo Chemical India reported a steady performance for the fiscal year ended March 31, 2026, with annual revenue growing 3% to ₹31,857.62 million. Net profit for the full year increased by 8.2% to ₹5,431.39 million, even after accounting for a one-time exceptional charge of ₹151.86 million related to new labor code regulations. The company's cash and cash equivalents nearly doubled to ₹675.29 million, indicating a strong liquidity position. The Board has recommended a dividend of ₹1.3 per share, maintaining its commitment to shareholder returns.
முக்கிய அம்சங்கள்
Annual Revenue from operations increased to ₹31,857.62 million in FY26 from ₹30,903.69 million in FY25.Net Profit for the full year rose to ₹5,431.39 million compared to ₹5,019.48 million in the previous year.The Board recommended a dividend of ₹1.3 per equity share (13% of face value) for FY 2025-26.Standalone Earnings Per Share (EPS) improved to ₹10.88 from ₹10.06 year-on-year.An exceptional item of ₹151.86 million was recognized due to the financial impact of new Government Labour Codes.
👀 கவனிக்க வேண்டியவை
Investors may find the steady growth and consistent dividend payout attractive, especially given the seasonal nature of the agro-chemical industry. It is advisable to monitor the legal proceedings regarding Glyphosate usage restrictions which remain a key product for the company.
Sumitomo Chemical India Announces Board Reappointments and MD Transition to Non-Executive Role
Sumitomo Chemical India has announced a planned leadership transition where current Managing Director Mr. Chetan Shah will move to a Non-Executive Director role starting September 1, 2026. The board has also reappointed Mr. N. Sivaraman as an Independent Director for a second three-year term and appointed Mr. Anand Mohan Tiwari as a new Independent Director for two years. These appointments aim to ensure continuity of expertise while refreshing the board's independent oversight. All appointments are subject to shareholder approval at the upcoming Annual General Meeting.
முக்கிய அம்சங்கள்
MD Chetan Shah to transition to Non-Executive Non-Independent Director effective September 1, 2026.Mr. N. Sivaraman reappointed as Independent Director for a 3-year term from 2026 to 2029.Mr. Anand Mohan Tiwari appointed as Independent Director for a 2-year term starting August 31, 2026.Mr. N. Sivaraman brings 42 years of finance experience, including past roles as MD & Group CEO at ICRA Limited.Mr. Anand Mohan Tiwari is a retired IAS officer with over three decades of experience in governance and the chemical sector.
👀 கவனிக்க வேண்டியவை
Investors should monitor for the announcement of the new Managing Director successor as Mr. Chetan Shah's executive term ends in August 2026. The moves indicate a structured succession plan which is generally positive for long-term stability.
Sumitomo Chemical India Promotes Dr. Suresh Ramachandran to Managing Director
Sumitomo Chemical India Limited has announced the promotion of Dr. Suresh Ramachandran to the position of Managing Director, effective September 1, 2026. Dr. Ramachandran, currently the Deputy Managing Director, has over 28 years of experience in the crop protection industry and holds a Ph.D. in Entomology. He joined the company in March 2021 as Chief Commercial Officer and has seen a steady rise through the leadership ranks. His appointment, which runs until May 31, 2028, is subject to shareholder approval via a special resolution.
முக்கிய அம்சங்கள்
Dr. Suresh Ramachandran promoted to Managing Director effective September 1, 2026Appointment term set from September 1, 2026, until May 31, 2028Brings over 28 years of industry experience including roles at Dow AgroSciences and Indofil IndustriesJoined SUMICHEM in March 2021 and was promoted to Deputy MD in September 2024Currently serves as Vice Chairman of the Agro Chem Federation of India
👀 கவனிக்க வேண்டியவை
Investors should view this internal promotion as a sign of leadership continuity and stability within the company. No immediate action is required as the transition is scheduled for late 2026.
Sumitomo Chemical India Declares Final Dividend of ₹1.30 Per Share for FY 2025-26
Sumitomo Chemical India Limited has recommended a final dividend of ₹1.30 per equity share for the financial year 2025-26. The dividend is declared on a total of 49,91,45,736 equity shares with a face value of ₹10 each. This payout is subject to the approval of shareholders at the upcoming Annual General Meeting. If approved, the dividend will be paid to eligible shareholders on or after August 3, 2026.
முக்கிய அம்சங்கள்
Recommended final dividend of ₹1.30 per equity share for the financial year 2025-26Dividend applicable to 49,91,45,736 equity shares of ₹10 eachPayment scheduled to be disbursed on or after August 3, 2026, post-AGM approvalBoard meeting concluded on May 26, 2026, at 04:46 P.M. to finalize the recommendation
👀 கவனிக்க வேண்டியவை
Investors should hold the stock to qualify for the dividend and watch for the announcement of the record date. The payout reflects the company's commitment to returning capital to shareholders.
Sumitomo Chemical Q3 Revenue Dips 12% to ₹568 Cr; Margins Expand to 47.4%
Sumitomo Chemical India reported a 12% YoY decline in Q3FY26 revenue to ₹568 crore, largely due to the strategic discontinuation of the low-margin Animal Nutrition distribution business and soft domestic demand. Despite the revenue dip, gross margins expanded significantly by 522 bps to 47.4% through a superior product mix and disciplined pricing. Net profit fell 13% YoY to ₹75.8 crore, weighed down by a one-time exceptional charge of ₹16.1 crore related to newly notified Labour Codes. The company provided clarity on its ₹160 crore capex projects, with commercialization expected between Q4 FY28 and Q2 FY29.
முக்கிய அம்சங்கள்
Q3FY26 revenue fell 12% YoY to ₹568 crore, while 9MFY26 revenue grew 3% to ₹2,555 crore.Gross margins improved to 47.4% in Q3 from 42.1% YoY, supported by the exit from the low-margin AND business (₹72 crore impact).Net Profit for Q3 stood at ₹75.8 crore, impacted by a ₹16.1 crore one-time exceptional charge for Labour Code compliance.Announced commercialization timelines for ₹150 crore Dahej project (Q2 FY29) and ₹10 crore Tarapur project (Q4 FY28).Maintains a strong balance sheet with cash and cash equivalents of approximately ₹2,163 crore as of December 31, 2025.
👀 கவனிக்க வேண்டியவை
Investors should focus on the significant margin expansion and the company's transition toward high-margin patented molecules from its parent company. While short-term domestic demand remains soft, the strong cash position and upcoming capex provide a solid long-term growth outlook.
Sumitomo Chemical Q3 PAT Falls 13% to ₹76 Cr on One-time Charge; Margins Expand 522 bps
Sumitomo Chemical India reported a 12% YoY decline in Q3FY26 revenue to ₹568 crore, largely due to the strategic discontinuation of the low-margin Animal Nutrition distribution business. Despite the revenue dip, gross margins expanded significantly by 522 bps to 47.4% due to a favorable product mix and disciplined pricing. Net profit fell 13% to ₹75.8 crore, primarily impacted by a one-time exceptional charge of ₹16.1 crore related to new Labour Code provisions. The company also announced a strategic ₹150 crore capex for its Dahej site to manufacture patented molecules for its Japanese parent company.
முக்கிய அம்சங்கள்
Q3 Revenue declined 12% YoY to ₹568 crore, impacted by a ₹72 crore revenue loss from discontinued low-margin business.Gross Profit Margin improved to 47.4% from 42.1% YoY, while EBITDA margin rose to 17.5%.Board approved ₹150 crore capex for a herbicide intermediate plant at Dahej for global supply to the parent company.Net Profit of ₹75.8 crore was affected by a ₹16.1 crore one-time exceptional charge; excluding this, PBT remained stable.Cash and cash equivalents stood at a robust ₹2,163 crore as of December 31, 2025.
👀 கவனிக்க வேண்டியவை
Investors should look past the headline PAT decline as it was driven by a one-time charge and the exit from low-margin segments. The significant margin expansion and the new capex for the parent company's patented molecules signal a positive long-term shift toward higher-value manufacturing.
Sumitomo Chemical India Files Q3 FY26 Results; Reports Zero Loan Defaults
Sumitomo Chemical India Limited has submitted its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board meeting concluded on January 27, 2026, confirming the approval of these results without any audit qualifications. The company reported zero deviations in the use of proceeds from public or preferential issues. Additionally, no defaults on loans or debt securities were reported for the period.
முக்கிய அம்சங்கள்
Board approved unaudited standalone and consolidated financial results for Q3 and 9M ended Dec 31, 2025Company confirmed zero outstanding defaults on loans and debt securities as of the reporting dateReported zero deviations or variations in the utilization of proceeds from public or rights issuesThe financial results were submitted with an unqualified audit opinion for the period ending December 2025Board meeting for result approval was conducted between 12:12 P.M. and 01:51 P.M. on January 27, 2026
👀 கவனிக்க வேண்டியவை
Investors should examine the detailed Annexure I for specific revenue and margin trends to assess operational performance. The lack of audit qualifications and debt defaults indicates a stable regulatory and credit profile.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
